terazosin has been researched along with indoramin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondinell, WE; Hieble, JP; Ruffolo, RR | 1 |
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Pedretti, A; Testa, B; Villa, L; Vistoli, G | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
| Clifford, GM; Farmer, RD | 1 |
4 review(s) available for terazosin and indoramin
| Article | Year |
|---|---|
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
Topics: Animals; Humans; Molecular Biology; Molecular Structure; Radioligand Assay; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1995 |
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
5 other study(ies) available for terazosin and indoramin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Topics: Chemical Phenomena; Chemistry, Physical; Ligands; Models, Molecular; Molecular Conformation; Monte Carlo Method; Quantitative Structure-Activity Relationship; Receptors, Adrenergic, alpha-1; Solvents | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |